Immunotherapy targets 'Invisible' leukemia to stop relapse
NCT ID NCT02458014
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This phase II trial tested blinatumomab in 36 adults with B-cell acute lymphoblastic leukemia who were in remission but still had tiny amounts of leukemia cells (minimal residual disease). The drug is an immunotherapy that helps the body's immune system find and destroy these hidden cancer cells. The main goal was to see if it could improve how long patients stay relapse-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blinatumomab (a type of immunotherapy that helps the immune system attack cancer cells)
What this could lead to
If successful, this could offer a way to eliminate hidden leukemia cells and delay or prevent relapse in patients who are otherwise in remission.
What could go wrong
This is a small, early-phase study (36 participants) with no control group, so results may not apply broadly. Blinatumomab can cause serious side effects like cytokine release syndrome or neurological problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.